Research Keyword: clinical implementation

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey

mycolabadmin

This study surveyed 2,800 Canadians about their views on using psilocybin (a psychedelic compound from certain mushrooms) to help patients with terminal illnesses manage existential distress and anxiety. About 79% of respondents thought it was a reasonable medical option, and 85% believed the government should cover the costs. People who had previous experience with psilocybin, those exposed to palliative care, and those with progressive political views were most supportive of this therapy.

Read More »

Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape

mycolabadmin

Australia has approved psilocybin as a treatment for severe depression, but the rollout faces major practical challenges. Only a handful of psychiatrists are authorized to prescribe it, treatment costs over $20,000 per person, and there are no standardized training programs for therapists. The therapy can profoundly alter patients’ beliefs and worldviews, raising ethical concerns about proper support during and after treatment. The article proposes solutions including national training standards, better funding access, and stronger safeguards for vulnerable patients.

Read More »

Clinical Implementation of Sustainable Functional Foods and Nutraceuticals in Metabolic Health: A Feasibility Study

mycolabadmin

Researchers tested a combination of special foods and supplements made from Mediterranean plants like tomatoes, pomegranates, and hazelnuts to see if they could help people with metabolic health problems. Over 4 weeks, older adults who consumed these foods daily showed improvements in muscle, bone quality, and liver health. The products tasted good and people stuck with them easily, suggesting this approach could be a practical way to improve health through diet.

Read More »

Virtual reality and psychedelics: new perspectives and new possibilities in the treatment of alcohol use disorder

mycolabadmin

This article discusses how virtual reality technology that simulates psychedelic experiences could improve treatment for alcohol addiction. Virtual reality simulations can mimic the brain effects of psychedelics like psilocybin, and could help prepare patients for treatment, extend its benefits, or even work as a standalone therapy. This innovation could make psychedelic-assisted therapy more accessible and easier to standardize across different treatment centers.

Read More »

A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia

mycolabadmin

Australia has recently approved psilocybin and MDMA for treating severe depression and PTSD when used with professional therapy support. This paper creates a comprehensive guide outlining all the regulatory, professional, and safety considerations needed to safely deliver these treatments in clinical settings. The researchers interviewed 11 experts and reviewed existing research to identify 102 specific matters that need clear guidelines, such as what qualifications therapists need, where treatments can be delivered, how patients should be screened, and what safety measures are essential.

Read More »
Scroll to Top